Edmond de Rothschild Investment Partners closed its first life sciences fund in 2000. Each successive fund has grown in size, and the firm has returned money to investors every year since 2004. EdRIP is looking to close BioDiscovery 4 this spring at €200 million ($267.6 million). Below are exits from its life science-focused BioDiscovery funds. (A) Total raised by company from all investors in indicated rounds; (B) Novexel S.A. is a BioDiscovery 2 and 3 portfolio company (C) U3 Pharma Inc. is a BioDiscovery 1 and 2 portfolio company; Sources: BCIQ: BioCentury Online Intelligence; company press releases; EdRIP

Company

Description

Round (A)

Exit

BioDiscovery 3 fund ($244.1M)

Novexel S.A. (B)

Anti-infectives against multi-drug resistant pathogens

Jan 2007 - $65M series B; 2009 - EdRIP, along with a syndicate of existing investors, bought out the stake of another investor for an undisclosed sum

March 2010 - acquired by AstraZeneca plc (LSE:AZN; NYSE:AZN) for up to $505M, including $75M in milestones